Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:

NCT ID: NCT05168761 Completed - Renal Cancer Clinical Trials

Complications Associated With Partial Nephrectomy for Renal Cancer

Start date: January 1, 2016
Phase:
Study type: Observational

This paper evaluates the initial complications and the complications two years postoperatively necessitating re-hospitalisation for three surgical procedures for renal tumour partial nephrectomy .

NCT ID: NCT05168436 Completed - Clinical trials for Renal Cell Carcinoma

A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal

Start date: August 5, 2019
Phase:
Study type: Observational

The purpose of this observational study is to determine patients' and professionals' preferences for the characteristics (attributes) of the treatment for Renal cell carcinoma (RCC) in Spain and Portugal.

NCT ID: NCT05070637 Completed - Clinical trials for Renal Cell Carcinoma

Circulating Tumor Cell Reducing No-touch Nephrectomy

CITO-CERENE
Start date: September 27, 2021
Phase: N/A
Study type: Interventional

This study will study circulating tumor cell (CTC) release during laparoscopic radical nephrectomy (LRN) for RCC. The main objective is to determine if CTC release can be reduced during RN by using a no-touch technique, with an early renal pedicle ligation. The investigators also aim to describe the CTC profile in terms of CTC count (CTCn), epithelial/mesenchymal status, and CTC cellular features in renal cell carcinoma (RCC) patients, stratified by "primary tumor, regional nodes, metastasis" (TNM) staging, histological subtype, and other clinical and radiological features. Patients undergoing RN will enter a two-arm prospective single-center randomized controlled trial (RCT), comparing a no-touch RN technique, with direct pedicle ligation (Group A) vs. the more conventional approach of kidney traction and manipulation to reach the renal pedicle before its ligation (Group B). A microfluidic size-based CTC isolation device will be used to capture and count CTCs from peripheral blood samples of these patients. CTCs will be identified by staining with antibodies to cytokeratin 8/18, vimentin, 4',6-diamidino-2-phenylindole (DAPI), and cluster of differentiation antigen 45 (CD45). CTC release will be correlated with the disease-free survival (DFS), and overall survival (OS). The investigators will determine if CTC reducing no-touch radical nephrectomy technique improves these hard outcomes.

NCT ID: NCT05042089 Completed - Clinical trials for Renal Malignant Tumor

Predictive Imaging Features in Renal Cell Carcinoma

Start date: May 1, 2021
Phase:
Study type: Observational

The investigators aimed to evaluate the role of some findings that can be detected in preoperative radiological imaging of kidney masses in predicting locally advanced disease.

NCT ID: NCT05025748 Completed - Clinical trials for Stage IV Breast Cancer

Ask Questions (ASQ):Implementation of a Communication Intervention

Start date: August 25, 2021
Phase: N/A
Study type: Interventional

This clinical trial implements a communication intervention to improve patient-oncologist communication in the outpatient medical oncology setting. A communication brochure called the ASQ brochure may help patients prepare for the doctor visit by thinking through the questions that patients and patients' family want to ask the doctor.

NCT ID: NCT05012865 Completed - Clinical trials for Renal Cell Carcinoma

Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)

Start date: September 14, 2021
Phase:
Study type: Observational

This study is a multicenter, non-interventional, retrospective, medical chart review of patients with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December 2019 and 20 December 2020. All decisions regarding clinical management and treatment of the participating patients were made by the investigator as part of standard care in real-world clinical setting and were not contingent upon the patient's participation in the study. Data will be collected if available per study site.

NCT ID: NCT04957160 Completed - Clinical trials for Advanced Renal Cell Carcinoma (aRCC)

Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

CARINA
Start date: September 9, 2021
Phase:
Study type: Observational

This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination therapy and progressed to a 2L treatment with particular focus to understanding where cabozantinib is prescribed after 1L IO containing combination therapy.

NCT ID: NCT04933604 Completed - Surgery Clinical Trials

LPN in Patients With High-complex Renal Tumors

Start date: September 1, 2019
Phase:
Study type: Observational

The study aims to investigate the rationale for LPN in patients with high-complexity renal tumors in terms of oncologic and functional outcomes.

NCT ID: NCT04873180 Completed - Clinical trials for Renal Cell Carcinoma

Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma

Start date: January 1, 2020
Phase:
Study type: Observational

detection of Survivin expression in renal cell carcinoma and correlate this expression to tumor grade and stage.

NCT ID: NCT04834778 Completed - Gastric Cancer Clinical Trials

A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

Start date: June 8, 2021
Phase: Phase 1
Study type: Interventional

Study HC-404-FCP-2011 is a first in human, Phase 1a, multi-center, open-label study to establish the maximum tolerated dose (MTD) and evaluate the safety and tolerability of oral dosing of HC-5404-FU in a dose-escalating fashion. Up to 36 qualified subjects at 3 to 5 US sites, who have specific tumor types of renal cell carcinoma (RCC), gastric cancer (GC), metastatic breast cancer (MBC), small cell lung cancer (SCLC), and other solid tumors (e.g., non-small cell lung cancer, colorectal cancer, carcinoma of unknown primary) with the exception of rapidly progressing neoplasms (e.g., pancreatic cancer, glioblastoma, hepatocellular carcinoma) will receive HC-5404-FU. Every effort will be made to ensure approximately 50% of all subjects enrolled will be subjects with RCC and GC. The starting dose level is 25 mg twice daily (BID), escalating to 50, 100, and 200 mg BID as safety allows, following the Bayesian Optimal Interval (BOIN) design. The safety monitoring committee (SMC) will evaluate the DLTs and cumulative safety and PK data at the end of each cohort. Based on the SMC recommendations after a comprehensive review of PK and safety data for 200 mg BID dose, higher dose levels will be evaluated, starting with 400 mg BID. The dose will escalate to 600 mg and then 900 mg following the BOIN design starting with 1 subject at each escalated dose, until the MTD is reached or the sponsor or SMC declares the dose most appropriate for clinical development. This Phase 1a will be expanded into a Phase 1b/2a study through a protocol amendment and will then assess the dose and tumor type(s) selected in Phase 1a as the most appropriate for further clinical development. Subjects will be dosed until unacceptable toxicity, disease progression per immune-related Response Evaluation Criteria in Solid Tumors (iRECIST), subject withdrawal, any other administrative reasons, or after 2 years of treatment, whichever occurs first. Efficacy will be assessed via Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1); computed tomography (CT) scans will be conducted every 6 weeks. Safety, including occurrence of dose-limiting toxicities (DLTs), pharmacokinetics (PK), and biomarker parameters will also be assessed.